Respivert Limited

Pulmocide Limited

Topivert Pharma Limited

1e Limited

Peter John Murray

Stuart Thomas Onions

Kazuhiro Ito

Peter Strong

John King-Underwood

Jonathan Gareth Williams

Catherine Elisabeth Charron

William Garth Rapeport

George Hardy

Euan Alexander Fraser Fordyce

Mihiro Sunose

Thomas Christopher Colley

Garth Rapeport

Simon Fraser Hunt

Vladimir Sherbukhin

Daniel William Brookes

Frederick Arthur Brookfield

Christopher John Brown

David Michel Adrien Taddei

Simon Christopher Hirst

Matthew Stephen Coates

Kevin Joly

Stephen Thom

Matthew Colin Thor Fyfe

Alistair Ian Longshaw

Lorna Duffy

Mick Saxton

Daniel Hamza

Ildiko Buck

Jennifer Claire Thomas

Ito Kazuhiro

Euan Alexander Fordyce

Claire Anne Marie Cariou

Hayley Tegan Angela Watson

David Michael Adrien Taddei

Stephen Malcolm Thom

Catherine Elizabeth Charron

A combination therapy including one or more compounds of formula (I): wherein R represents hydrogen, halo, cyano, Chaloalkyl, Chaloalkoxy, or SONRR, Rand Rindependently represent hydrogen or halo; Rrepresents hydrogen, halo, cyano, Calkyl, Calkoxy, or Chaloalkoxy; Rrepresents halo, cyano, Calkyl, or Chydroxyalkyl; Rrepresents hydrogen or Calkyl; X represents CH or N; Y represents N or CH which carbon atom may optionally be substituted by R, Ror R; Rand Rindependently represent hydrogen or Calkyl; or a pharmaceutically acceptable salt thereof; and a second or further active ingredient.

Process for preparing a compound useful to treat mycoses

A process for preparing a compound of formula (II): includes reacting a compound of formula (VIII): with a compound of formula (XIV): 

A process for preparing a compound of formula (II):  includes reacting a compound of formula (VIII):  with a compound of formula (XIV): 

A process for preparing a compound of formula (I): includes reacting a compound of formula (II): with a compound of formula (III): 

There are provided 5,6-dihydro-4H-dithieno[3,2-b:2',3&#x2032;-d]azepine derivatives(as defined in the disclosure) which are useful in the treatment of RSV infection and for the prevention of disease associated with RSV infection.

Compounds

There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (I)). 

5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative

A compound of formula (II): or a compound of formula (IV): or a compound of formula (XX): is useful in the treatment of mycoses.

Compound useful to treat mycoses

The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).

Respiratory formulations and compounds for use therein

There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (1)). 

There are provided 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives which are useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. 

5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives

There is provided inter alia a compound of formula (I): wherein R, J, Ar, L, X, Rand Rare as defined in the specification, for use in the treatment of inflammatory disorders.

P38 MAP kinase inhibitors

This invention relates to compounds, as defined in the specification and as represented by the compound of formula (I): that are useful in the treatment of mycoses, compositions containing them and their use in therapy.

The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.

Growing community of inventors

London, United Kingdom

Peter John Murray